Prior studies have delivered an IL-15 superagonist intravenously or subcutaneously and have used dosing regimens in combination with PD-1/PD-L1; however, these studies have shown that increased survival and tumor immunity were short-lived [30]. This evidence concerns the gene IL15 and neoplasm.